An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Intervention/treatment:
LY3074828 (MIRIKIZUMAB)
Medical condition:
ULCERATIVE COLITIS
Protocol code:
I6T-MC-AMAN
Control number:
215996
Status:
Closed
Approved:
June 01, 2018
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03518086
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 80 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Chief Medical Officer
Organization
Eli Lilly and Company
Phone:
800-545-5979
Sponsor
ELI LILLY CANADA INC

Locations

Alberta

Gastroenterology and internal medicine research institute
Edmonton, Alberta, T5R 1W2

British Columbia

GI Research Institute
Vancouver, British Columbia, V6Z 2K5
PerCuro Clinical Research
Victoria, British Columbia, V8V 3M9
The Gordon and Leslie Diamond Health Care Centre
Vancouver, British Columbia, V5Z 1M9

Ontario

University of Western Ontario
London, Ontario, N6A 5G1
Victoria Hospital
London, Ontario, N6A 4G5

Quebec

Centre de santé et de services sociaux Champlain-Charles-Le Moyne
Greenfield Park, Quebec, J4V 2H1
Hopital Maisonneure-Rosemount
Montreal, Quebec, H1T 2M4
Inflammatory Bowel Disease Centre Montreal General Hospital - MUHC
Montreal, Quebec, H3G 1A4

Results

See the results from the trial NCT03518086. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?